echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > In the future, innovation in the pharmaceutical field will be the king, and the R & D investment of domestic pharmaceutical enterprises will grow steadily

    In the future, innovation in the pharmaceutical field will be the king, and the R & D investment of domestic pharmaceutical enterprises will grow steadily

    • Last Update: 2020-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network market analysis] in recent years, with the promotion of drug review reform, MAH, priority review and other policies, China's innovative drug industry has ushered in good opportunities for development At the same time, with the rapid entry of the competitors of multinational pharmaceutical enterprises, domestic enterprises are also forced to increase R & D investment to improve market competitiveness, the quality of drugs is constantly improving, and the price of drugs is declining In the future, the innovation in the pharmaceutical field will be Wang 2020, and the second tire quantity procurement variety is expected to land in April The industry believes that with the normalization of policies such as centralized procurement, supply side reform of China's pharmaceutical industry will be further accelerated, and innovative drugs will become an important development direction At the same time, with the continuous release and implementation of policies to encourage drug R & D innovation, domestic drug R & D ushers in good opportunities In general, innovation in the pharmaceutical field will prevail in the future, and the innovative drug market will continue to release vitality At present, the domestic pharmaceutical companies represented by Hengrui pharmaceutical, Fosun Pharmaceutical and China biopharmaceutical are seizing the opportunity to continuously increase R & D investment and accelerate the construction and listing process of product pipeline In addition, Baiji Shenzhou, Xinda biology, Geli pharmaceutical and other enterprises, with the help of capital, are also striving to speed up the promotion of innovation pipeline The R & D investment of domestic pharmaceutical enterprises is growing steadily With the coming of the era of "product is king" driven by innovation, industrial transformation and upgrading has become a trend In recent years, the proportion of R & D investment of large pharmaceutical enterprises in China has been increasing year by year, and the growth rate of R & D investment is also constantly reaching a new high Taking Hengrui pharmaceutical as an example, the R & D proportion of the leading innovative pharmaceutical enterprises is nearly 15%, close to the R & D investment level of multinational pharmaceutical enterprises, and the growth rate of R & D investment is stable at more than 50%; Fosun Pharmaceutical has made synchronous progress with Hengrui pharmaceutical with almost the same R & D investment, and entered the field of new drugs Fosun said that in the current trend of generic drug price reconstruction, the company will adhere to high R & D investment and strengthen innovation and R & D According to the comparable R & D investment of 266 pharmaceutical listed companies in the industry statistics, since the start of drug audit reform, the R & D investment of these pharmaceutical companies has maintained a sustained and rapid growth, of which the total R & D investment in 2018 and the first three quarters of 2019 was 39.13 billion yuan and 25.94 billion yuan, with a year-on-year growth of 35.33% and 25.61% The industry believes that in the long run, with innovation becoming the theme direction of the pharmaceutical industry, the R & D investment of pharmaceutical companies is expected to continue to maintain a high-speed growth trend in the future In addition, considering that the Hong Kong Stock Exchange allowed the IPO of non-profit biotechnology companies in the first half of 2018 and the new technology innovation board set up by the Shanghai Stock Exchange in 2019, new financing channels have been opened for some small and medium-sized companies It is expected that the fund-raising costs of these pharmaceutical companies will be converted into R & D costs in the next 3-5 years However, it is worth mentioning that although many domestic pharmaceutical enterprises have a substantial increase in R & D innovation investment in recent years, compared with international pharmaceutical innovation giants, China's pharmaceutical innovation is still in the primary stage in resource accumulation and R & D investment According to the industry classification of Shenwan in wind database, the total R & D investment of all A-share pharmaceutical and biological companies in 2017 was RMB 32 billion, less than that of a multinational company Of course, it has something to do with the characteristics of the scattered number and small scale of pharmaceutical enterprises in China But in the overall direction, domestic pharmaceutical companies need to break the past development model, continue to strengthen R & D investment and improve innovation level.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.